Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH)
Rocío Gallego-Durán 1, Agustín Albillos 2, Javier Ampuero 3, María Arechederra 4, Rafael Bañares 5, Ana Blas-García 6, Genoveva Berná 7, Esther Caparrós 8, Teresa C Delgado 9, Juan Manuel Falcón-Pérez 10, Rubén Francés 8, Maite G Fernández-Barrena 4, Isabel Graupera 11, Paula Iruzubieta 12, Yulia A Nevzorova 13, Rubén Nogueiras 14, Rocío I R Macías 15, Franz Martín 7, Guadalupe Sabio 16, Germán Soriano 17, Javier Vaquero 18, Francisco Javier Cubero 19, Jordi Gracia-Sancho 20
This is a meeting report of the 3rd Translational Hepatology Meeting held in Alicante, Spain, in October 2021. The meeting, which was organized by the Spanish Association for the Study of the Liver (AEEH), provided an update on the recent advances in the field of basic and translational hepatology, with a particular focus on the molecular and cellular mechanisms and therapeutic targets involved in metabolic-associated fatty liver disease (MAFLD), metabolic-associated steatohepatitis (MASH), cirrhosis and end-stage hepatocellular carcinoma (HCC).
Keywords: Carcinoma hepatocelular; Esteatohepatitis; Esteatosis; Fibrosis; Hepatocellular carcinoma; MAFLD; MASH; Steatohepatitis.